Risperdal Lawsuit Alleges Teen Diagnosed With Gynecomastia

A Louisiana mother is one of the latest to file a product liability lawsuit that alleges side effects of Risperdal caused her teenage son to develop gynecomastia, which is a medical condition associated with the growth of breast among males. 

The complaint (PDF) was filed in the U.S. District Court for the Eastern District of Louisiana on December 17, indicating that the unidentified minor child of a Jefferson Parish woman was diagnosed with gynecomastia after being prescribed Risperdal, it’s injectable version Risperdal Consta, as well as the antipsychotic Invega and generic Risperidrone by various health care providers.

Johnson & Johnson, it’s Janssen Pharmaceuticals unit, Patriot Pharmaceuticals, Breen Distribution and Endo Pharmaceuticals, Inc. have all been named as defendants.

Learn More About

Risperdal Lawsuits

Side effects of Risperdal linked to risk of breast growth among young boys, or gynecomastia.

Learn More About this Lawsuit SEE IF YOU QUALIFY FOR COMPENSATION

Gynecomastia side effects from Risperdal can cause the benign enlargement of breast tissue in males, not only causing physical injury, but also often resulting in severe psychological damage for the child.

Allegations raised in the complaint are similar to those brought in hundreds of other Risperdal lawsuits filed in recent years by young men or families of children diagnosed with this rare condition, indicating that the drug manufacturers withheld important information about the risk of abnormal breast growth among boys prescribed the atypical antipsychotic.

Risperdal (risperidone) and Invega (paliperidone) are atypical antipsychotic medications originally introduced for adults with schizophrenia. However, the medications have been widely used by children for bi-polar disorders, autism, irritability, aggression and behavior disorders.

Morris’s case joins a growing number of Risperdal gynecomsatia lawsuits being pursued in courts throughout the country on behalf of boys and young men who have experienced problems, with some of the complaints alleging that the drug caused the development of breasts as large as 38D cup size.

Most of the Risperdal litigation has been filed in Pennsylvania state court, where more than 1,000 gynecomastia cases are currently pending in the Philadelphia Court of Common Pleas, where a series of early trial dates are expected to begin next year to help the parties gauge how juries may respond to certain evidence and testimony that is likely to be repeated throughout the cases.

While the outcomes of these early trial dates are not binding on other lawsuits, they may help promote negotiations to reach Risperdal settlements that avoid the need for hundreds of cases to go to trial.

This most recent Risperdal lawsuit pursues claims against the drug makers for manufacturing and designing a defective product, failure to warn, breach of warranty, strict liability, and violating federal regulations, seeking compensatory damages for past, present and future medical expenses, physical pain and suffering, mental anxiety and anguish, lost wages and earnings, loss of earning capacity, loss of enjoyment of life, and loss of consortium.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted yesterday)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.

Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October
Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October (Posted yesterday)

A U.S. District Court judge has scheduled a fairness hearing for October in order to determine whether final approval should be granted to a $25 million Philips CPAP recall settlement agreement, which would pay former users $25 million to pay for future medical monitoring needs.

Abbott Laboratories Faces Jury Trial Over Claims Similac Caused NEC For Premature Infant
Abbott Laboratories Faces Jury Trial Over Claims Similac Caused NEC For Premature Infant (Posted 2 days ago)

Following a $60 million verdict in a similar lawsuit earlier this year, trial is underway involving claims brought by an Illinois mother, whose premature daughter developed NEC from Similac, alleging that Abbott failed to warn parents and medical staff of the devastating risks associated with the cow's milk-based formula.